ShehabAYasinJHashimMJ. Gender differences in acute coronary syndrome in Arab Emirati women – implications for clinical management. Angiology. 2012;DOI: 10.1177/0003319712443891
2.
ClaassenMSybrandyKCAppelmanYEAsselbergsFW. Gender gap in acute coronary heart disease: myth or reality?World J Cardiol. 2012;4(2):36–47.
3.
RogerVLGoASLloyd-JonesDM. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18–e209.
4.
SytkowskiPAD'AgostinoRBBelangerAKannelWB. Sex and time trends in cardiovascular disease incidence and mortality: The Framingham Heart Study, 1950-1989. Am J Epidemiol. 1996;143(4):338–350.
5.
ShawLJBairey MerzCNPepineCJ. Insights from the nhlbi-sponsored women’s ischemia syndrome evaluation (WISE) study: Part I: Gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006;47(3 suppl):S4–S20.
6.
McQueenMJHawkenSWangX. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634):224–233.
7.
AnandSSIslamSRosengrenA. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J. 2008;29(7):932–940.
8.
DubeyRKImthurnBBartonMJacksonEK. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res. 2005;66(2):295–306.
9.
DubeyRKJacksonEK. Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms. Am J Physiol Renal Physiol. 2001;280(3):F365–F388.
10.
MendelsohnMEKarasRH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340(23):1801–1811.
11.
VassalleCSimonciniTChedrauiPPerez-LopezFR. Why sex matters: the biological mechanisms of cardiovascular disease [published online ahead of print February 14, 2012]. Gynecol Endocrinol. 2012.
12.
Barrett-ConnorEBushTL. Estrogen and coronary heart disease in women. JAMA. 1991;265(14):1861–1867.
13.
Barrett-ConnorEGradyD. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health. 1998;19:55–72.
14.
RossouwJEAndersonGLPrenticeRL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
15.
HochmanJSTamisJEThompsonTD. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global use of strategies to open occluded coronary arteries in acute coronary syndromes IIB investigators. N Engl J Med. 1999;341(4):226–232.
16.
PrescottEHippeMSchnohrPHeinHOVestboJ. Smoking and risk of myocardial infarction in women and men: Longitudinal population study. BMJ. 1998;316(7137):1043–1047.
17.
HuxleyRBarziFWoodwardM. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73–78.
18.
HaunerH. Insulin resistance and the metabolic syndrome—a challenge of the new millennium. Eur J Clin Nutr. 2002;56(suppl 1):S25–S29.
19.
MenteAYusufSIslamS. Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. J Am Coll Cardiol. 2010;55(21):2390–2398.
20.
AthyrosVGGanotakisESElisafMMikhailidisDP. The prevalence of the metabolic syndrome using the national cholesterol educational program and international diabetes federation definitions. Curr Med Res Opin. 2005;21(8):1157–1159.
21.
JanssenIPowellLHCrawfordSLasleyBSutton-TyrrellK. Menopause and the metabolic syndrome: The study of Women’s Health across the nation. Arch Intern Med. 2008;168(14):1568–1575.
22.
ZaliunasRSlapikasRBabarskieneR. The prevalence of the metabolic syndrome components and their combinations in men and women with acute ischemic syndromes. Medicina (Kaunas). 2008;44(7):521–528.
23.
YasminSMallickNHNaveedTAliMNomanAShakoorT. Metabolic syndrome in patients with ischemic heart disease. J Coll Physicians Surg Pak. 2008;18(10):605–607.
24.
CaminitiGVolterraniMMarazziG. Metabolic syndrome predicts lower functional recovery in female but not in male patients after an acute cardiac event. Int J Cardiol. 2009;135(3):296–301.
25.
KostapanosMSElisafMSMikhailidisDP. Obstructive sleep apnea and cardiovascular risk: is metabolic syndrome the link? [published online ahead of print February 8, 2012]. Angiology. 2012.
26.
NenaEPapanasNSteiropoulosP. Mean platelet volume and platelet distribution width in non-diabetic subjects with obstructive sleep apnoea syndrome: new indices of severity? [published online ahead of print November 10, 2011]. Platelets. 2011.
27.
SinDDManSF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005;2(1):8–11.
28.
SinDDManSF. Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Can J Physiol Pharmacol. 2005;83(1):8–13.
29.
ChouAFWongLWeismanCS. Gender disparities in cardiovascular disease care among commercial and medicare managed care plans. Womens Health Issues. 2007;17(3):139–149.
30.
KonesR. Recent advances in the management of chronic stable angina. i: approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities. Vasc Health Risk Manag. 2010;6:635–656.
31.
MilnerKAVaccarinoVArnoldALFunkMGoldbergRJ. Gender and age differences in chief complaints of acute myocardial infarction (Worcester heart attack study). Am J Cardiol. 2004;93(5):606–608.
32.
BosnerSHaasenritterJHaniMA. Gender differences in presentation and diagnosis of chest pain in primary care. BMC Fam Pract. 2009;10:79.
33.
KakafikaAIAthyrosVGTziomalosKKaragiannisAMikhailidisDP. Primary and secondary coronary heart disease prevention using statins: is targeting adam or eve equally effective?Expert Opin Pharmacother. 2008;9(9):1437–1440.
34.
DorschMPLeeJSLynchDR. Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann Pharmacother. 2007;41(5):737–741.
35.
RidkerPMCookNRLeeIM. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293–1304.
36.
BergerJSRoncaglioniMCAvanziniFPangrazziITognoniGBrownDL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306–313.
37.
MoscaLBankaCLBenjaminEJ. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115(11):1481–1501.
38.
TziomalosKKakafikaAIAthyrosVGKaragiannisAMikhailidisDP. The role of statins for the primary and secondary prevention of coronary heart disease in women. Curr Pharm Des. 2009;15(10):1054–1062.
39.
MoraSGlynnRJHsiaJMacFadyenJGGenestJRidkerPM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: Results from the Justification for the Use of statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121(9):1069–1077.
40.
AthyrosVGKakafikaAIPapageorgiouAA. Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE study. Curr Med Res Opin. 2008;24(6):1593–1599.
RadovanovicDErnePUrbanPBertelORickliHGaspozJM. Gender differences in management and outcomes in patients with acute coronary syndromes: results on 20,290 patients from the AMIS plus registry. Heart. 2007;93(11):1369–1375.
43.
KolovouGDMihasCKotanidouA. Mortality after first myocardial infarction in Greek patients: a 4-year follow-up study. Angiology. 2009;60(5):582–587.
44.
De LucaGGibsonCMGyongyosiM. Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: insights from the Egypt cooperation. J Thromb Thrombolysis. 2010;30(3):342–346.
